Agilent to expand portfolio in cell analysis
Agilent Technologies Inc. has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc., a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. Since its inception in
2002, ACEA has launched two ground-breaking, highly differentiated platforms. ACEA is revolutionizing the field of flow cytometry with its high-performance, customizable line of NovoCyte benchtop flow cytometers. ACEA’s xCELLigence instruments enable label-free, real-time monitoring of cell growth, cell function, and cellular responses to a variety of treatments, providing scientists informationrich cellular assays.
ACEA instruments are used worldwide in both academia and industry across a wide range of life science applications from basic research to clinical diagnostics including preclinical drug discovery and development, toxicology & safety pharmacology, and various disease studies. ACEA is headquartered in San Diego and has a large manufacturing and R&D footprint in Hangzhou, China.